MedTrace Logo

Glutamate for Metabolic Intervention in Coronary Surgery

NCT00489827 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 865

Last updated 2024-05-22

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to determine whether intravenous glutamate infusion given in association with surgery for unstable coronary artery disease can protect the heart from myocardial injury, postoperative heart failure and death.

Conditions

Interventions

DRUG

Intravenous infusion of saline

Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.

OTHER

Intravenous glutamate infusion

Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.

Sponsors & Collaborators

  • Region Örebro County

    collaborator OTHER

  • Blekingesjukhuset, Karlskrona

    collaborator UNKNOWN

  • University Hospital, Linkoeping

    lead OTHER

Principal Investigators

  • Rolf Svedjeholm, MD PhD · University Hospital, Linkoeping

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2009-12-31
Completion
2022-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00489827 on ClinicalTrials.gov